Leebeek F - Search Results

1

Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions.

Rudez G, Pons D, Leebeek F, Monraats P, Schrevel M, Zwinderman A, de Winter R, Tio R, Doevendans P, Jukema W, de Maat M. Rudez G, et al. Among authors: leebeek f. Hum Mutat. 2008 Mar;29(3):375-80. doi: 10.1002/humu.20641. Hum Mutat. 2008. PMID: 18175333

2

Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris.

Brouwers GJ, Leebeek FW, Tanck MW, Wouter Jukema J, Kluft C, de Maat MP. Brouwers GJ, et al. Thromb Haemost. 2003 Jul;90(1):92-100. Thromb Haemost. 2003. PMID: 12876631

3

Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity.

Lisman T, Bongers TN, Adelmeijer J, Janssen HL, de Maat MP, de Groot PG, Leebeek FW. Lisman T, et al. Hepatology. 2006 Jul;44(1):53-61. doi: 10.1002/hep.21231. Hepatology. 2006. PMID: 16799972

4

High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability.

Bongers TN, de Maat MP, van Goor ML, Bhagwanbali V, van Vliet HH, Gómez García EB, Dippel DW, Leebeek FW. Bongers TN, et al. Stroke. 2006 Nov;37(11):2672-7. doi: 10.1161/01.STR.0000244767.39962.f7. Epub 2006 Sep 21. Stroke. 2006. PMID: 16990571

5

Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.

de Bruijne EL, Darwish Murad S, de Maat MP, Tanck MW, Haagsma EB, van Hoek B, Rosendaal FR, Janssen HL, Leebeek FW; Liver and Thrombosis Study Group. de Bruijne EL, et al. Thromb Haemost. 2007 Feb;97(2):181-5. Thromb Haemost. 2007. PMID: 17264944

6

Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders.

Auwerda JJ, Sonneveld P, de Maat MP, Leebeek FW. Auwerda JJ, et al. Clin Lymphoma Myeloma. 2007 Jul;7(7):462-6. doi: 10.3816/clm.2007.n.027. Clin Lymphoma Myeloma. 2007. PMID: 17875234

7

Fibrinogen gamma' in ischemic stroke: a case-control study.

Cheung EY, Uitte de Willige S, Vos HL, Leebeek FW, Dippel DW, Bertina RM, de Maat MP. Cheung EY, et al. Stroke. 2008 Mar;39(3):1033-5. doi: 10.1161/STROKEAHA.107.495499. Epub 2008 Jan 31. Stroke. 2008. PMID: 18239174

8

Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens.

van Marion AM, Auwerda JJ, Lisman T, Sonneveld P, de Maat MP, Lokhorst HM, Leebeek FW. van Marion AM, et al. Leuk Res. 2008 Jul;32(7):1078-84. doi: 10.1016/j.leukres.2007.12.002. Epub 2008 Feb 1. Leuk Res. 2008. PMID: 18241919 Clinical Trial.

9

Variation in fibrinogen FGG and FGA genes and risk of stroke: the Rotterdam Study.

Cheung EY, Bos MJ, Leebeek FW, Koudstaal PJ, Hofman A, de Maat MP, Breteler MM. Cheung EY, et al. Thromb Haemost. 2008 Aug;100(2):308-13. Thromb Haemost. 2008. PMID: 18690352

10

Strongly increased levels of fibrinogen elastase degradation products in patients with ischemic stroke.

de Lau LM, Cheung EY, Kluft C, Leebeek FW, Meijer P, Laterveer R, Dippel DW, de Maat MP. de Lau LM, et al. Br J Haematol. 2008 Dec;143(5):734-7. doi: 10.1111/j.1365-2141.2008.07395.x. Br J Haematol. 2008. PMID: 19036017 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

452 results

Search Page

Filters